Multiple Sclerosis and Medical Marijuana: Can Cannabis Help MS Symptoms?
Multiple sclerosis (MS) is one of the most significant neurological conditions affecting young and middle-aged adults, with approximately one million Americans living with the disease. MS causes unpredictable neurological symptoms including muscle spasticity, chronic pain, fatigue, and bladder dysfunction that profoundly impair quality of life. Medical cannabis has become one of the most closely studied complementary therapies for MS, and it is among the most universally recognized qualifying conditions across state medical marijuana programs. This guide covers the neuroscience of cannabis and MS, the clinical evidence for specific symptoms, which states qualify MS patients for medical marijuana, and how Elevate Holistics can help you get your card quickly and affordably.
Understanding Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune disease in which the body’s immune system mistakenly attacks the myelin sheath, the protective coating that surrounds and insulates nerve fibers in the brain and spinal cord. This demyelination disrupts the transmission of nerve signals, causing a wide range of neurological symptoms that vary depending on which nerves are affected and the extent of damage.
MS typically follows one of four disease courses:
- Relapsing-Remitting MS (RRMS) – The most common form, affecting about 85% of patients at diagnosis. Characterized by clearly defined periods of new or worsening symptoms (relapses) followed by partial or complete recovery (remissions).
- Secondary Progressive MS (SPMS) – Initially relapsing-remitting, but transitions to a steadily worsening course with fewer relapses.
- Primary Progressive MS (PPMS) – Progressive disability from onset without distinct relapses, affecting about 10-15% of patients.
- Progressive-Relapsing MS (PRMS) – Rare form with steady progression from onset plus occasional acute relapses.
Common MS symptoms include muscle spasticity and weakness, chronic neuropathic pain, fatigue (a particularly disabling feature of MS), bladder and bowel dysfunction, visual disturbances, cognitive impairment, tremor, balance and coordination problems, depression, and sexual dysfunction. While disease-modifying therapies (DMTs) can reduce relapse rates and slow progression in some MS types, they do not address the symptom burden that significantly impairs daily functioning.
The Endocannabinoid System and MS Pathology
The central nervous system, the primary site of MS pathology, is rich in endocannabinoid receptors. CB1 receptors are highly expressed in the brain regions responsible for motor control, sensory processing, and pain modulation. CB2 receptors are found on immune cells including the microglia and macrophages that play a central role in the inflammatory process driving MS lesion formation.
Research has found altered endocannabinoid levels in the cerebrospinal fluid of MS patients during relapses, suggesting that the ECS is actively involved in the disease process and that endocannabinoid tone may be insufficient to fully counter the inflammatory and excitotoxic insults occurring in MS tissue. This biological context supports the rationale for cannabinoid therapy in MS.
Preclinical work in animal models of MS has shown that cannabinoids can reduce demyelination, suppress neuroinflammation, protect against axonal loss, and reduce spasticity. While these findings have not been fully replicated in human disease-progression studies, they contribute to ongoing interest in cannabis as potentially neuroprotective in addition to symptomatic.
We Have a 99% Approval Rate
Clinical Evidence for Cannabis and MS
Spasticity
MS-related spasticity is the symptom for which cannabis has the strongest clinical evidence. The pivotal evidence comes from clinical trials of nabiximols (Sativex), a 1:1 CBD:THC oromucosal spray developed specifically for MS spasticity. Multiple randomized controlled trials, including the large MUSEC trial and the MOVE 2 study, demonstrated that nabiximols significantly reduced spasticity scores, reduced the frequency of spasms, and improved mobility compared to placebo. Based on this evidence, nabiximols has been approved for MS spasticity in the UK, Canada, Germany, Spain, Italy, and more than 25 other countries.
A 2018 Cochrane review of cannabis-based medicines in MS found good evidence for short-term benefit on spasticity measures, further supporting the clinical utility of cannabinoids for this symptom.
Neuropathic Pain
Neuropathic pain, caused by damaged or dysfunctional nerve fibers, is experienced by up to 50-70% of people with MS and is often refractory to conventional analgesics. Multiple clinical trials have demonstrated that cannabis-based medicines reduce neuropathic pain scores in MS patients, with a favorable responder profile compared to placebo.
Bladder Dysfunction
Neurogenic bladder, affecting control and frequency of urination, is a common and distressing MS complication. Clinical research, including a randomized trial published in the European Urology journal, found that nabiximols significantly reduced urinary incontinence episodes per day in MS patients compared to placebo.
Sleep
Pain and spasticity frequently disrupt sleep in MS. Several trials examining cannabis for MS pain or spasticity also reported significant secondary improvements in sleep quality, suggesting that cannabis addresses sleep disruption both directly and indirectly by managing the symptoms that prevent restful sleep.
Tremor and Fatigue
Evidence is more mixed for MS-related tremor and fatigue. Some studies report modest benefits, while others show no significant effect. Individual responses vary, and these symptoms remain an area of active investigation.
States Where Multiple Sclerosis Qualifies for Medical Marijuana
Multiple sclerosis is one of the most uniformly recognized qualifying conditions across the United States. It appears on the qualifying condition list in virtually every state with a comprehensive medical marijuana program, including:
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia (limited), Hawaii, Illinois, Louisiana, Maine, Maryland, Michigan, Minnesota, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Virginia, Washington, West Virginia, and Washington D.C.
If you have an MS diagnosis, the path to qualification is typically straightforward. You will need documentation of your diagnosis from a neurologist or other licensed physician, which you bring to your Elevate Holistics online appointment.
Practical Guidance: Using Medical Cannabis for MS
Patients with MS seeking medical cannabis guidance should consider the following practical points:
- Start low, go slow – MS patients on multiple medications should be especially cautious about drug interactions. CBD can affect the metabolism of certain medications, and THC can cause dizziness or cognitive effects that may worsen existing MS symptoms in some patients.
- Balanced CBD:THC products – A 1:1 ratio, similar to nabiximols, is the most clinically studied approach for spasticity and pain in MS. Pure CBD products may be more suitable for patients concerned about psychoactive effects.
- Timing matters – For sleep-disrupting spasticity or pain, evening doses of THC-containing products may be most appropriate. Daytime symptom management may benefit more from higher CBD ratios.
- Discuss with your neurologist – Because MS requires ongoing disease monitoring and neurologists adjust DMTs based on disease activity and side effects, it is important to keep your neurologist informed about cannabis use.
Better MS Symptom Management Starts Here
Multiple sclerosis presents unique daily challenges, but medical cannabis offers evidence-backed relief for some of its most debilitating symptoms. At Elevate Holistics, our licensed physicians understand the complexity of MS management and can guide you through the qualification process with knowledge and compassion.
Book your appointment online today. Our appointments take 30 minutes or less, your certification is delivered digitally, and if you do not qualify, you pay nothing. Join over 125,000 patients who have trusted Elevate Holistics for their medical marijuana certification.
Get Approved for Medical Marijuana Treatment
Frequently Asked Questions About Medical Marijuana and Multiple Sclerosis
Is multiple sclerosis a qualifying condition for a medical marijuana card?
Yes. Multiple sclerosis is one of the most consistently recognized qualifying conditions across U.S. state medical marijuana programs. States including Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Louisiana, Maine, Maryland, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Virginia, Washington, West Virginia, and Washington D.C. all recognize MS as qualifying.
What MS symptoms can medical marijuana help with?
Medical marijuana has demonstrated particular benefit for MS-related spasticity, neuropathic pain, bladder dysfunction, and sleep disruption. Spasticity is the best-studied MS symptom for cannabis, with multiple randomized controlled trials supporting efficacy. Cannabis may also help manage fatigue, anxiety, and mood disturbances associated with MS.
Is Sativex available in the U.S. for multiple sclerosis?
Sativex (nabiximols) is approved for MS-related spasticity in over 25 countries but is not yet FDA-approved in the United States. However, MS patients in states with medical marijuana programs can access cannabis products with similar CBD:THC ratios through licensed dispensaries with a physician's recommendation.
Does cannabis affect MS disease progression?
Current research supports cannabis primarily as a symptomatic treatment for MS rather than a disease-modifying therapy. MS patients should continue disease-modifying therapies as prescribed by their neurologist and use cannabis as a complementary approach to symptom management.
How should I take medical cannabis for MS spasticity?
For MS spasticity, sublingual tinctures or oromucosal sprays with a balanced CBD:THC ratio are most commonly recommended based on clinical research. Vaporization is used by some patients for faster-onset relief during acute spasm episodes. Always work with a licensed physician to identify the appropriate formulation and dose.